External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
Marinus J HagensPiter J StelwagenHans VeermanSybren P RynjaMartijn SmeengeVincent van der NoortTon A RoeleveldJolien van KesterenSebastiaan RemmersMonique J RoobolPim J van LeeuwenHenk G van der PoelPublished in: World journal of urology (2022)
The RPCRC-3/4 underestimates the probability of having csPCa within this Dutch clinical cohort, resulting in significant numbers of csPCa diagnoses being missed. For optimal performance of a risk calculator in a specific cohort, evaluation of its performance within the population under study is essential.
Keyphrases